Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy

Clinical Gastroenterology and Hepatology - United Kingdom
doi 10.1016/j.cgh.2017.05.017
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Gastroenterology
HepatologyGastroenterology
2017English

Self-Fulfilling Prophecy

English

Pregnancy Outcomes in Women With Inflammatory Bowel Disease Treated With Biosimilar Infliximab

Gastroenterologie a Hepatologie
HepatologyGastroenterology
2018English

OC16.06: Macrosomia: A Self-Fulfilling Prophecy

Ultrasound in Obstetrics and Gynecology
Nuclear MedicineRadiologyUltrasound TechnologyGynecologyReproductive MedicineRadiologicalImagingObstetricsMedicine
2018English

Editorial: Infliximab De-Escalation in Inflammatory Bowel Disease Using a Therapeutic Drug Monitoring Strategy - Early Promise but More Data Needed. Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Renal Tubular Dysfunction in Patients With Inflammatory Bowel Disease Treated With Aminosalicylate.

Gut
Gastroenterology
1997English

Suppression of Anti-Drug Antibodies to Infliximab or Adalimumab With the Addition of an Immunomodulator in Patients With Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Letter: Therapeutic Drug Monitoring and Inflammatory Bowel Disease-A Call for an Urgent Standardization of the Results

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy